<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3554">
  <stage>Registered</stage>
  <submitdate>19/05/2012</submitdate>
  <approvaldate>19/05/2012</approvaldate>
  <nctid>NCT01604746</nctid>
  <trial_identification>
    <studytitle>Additional 6-Month Safety Follow-up After Completion of Precursor Study 880801</studytitle>
    <scientifictitle>Open-label Phase 3b Study to Investigate the Safety of Ross River Virus (RRV) Vaccine From 6 to 12 Months After the Third Vaccination in Healthy Adults (Follow up to Precursor Study 880801)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>881201</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Prophylaxis of Ross River Virus Infection</healthcondition>
  </conditions>
  <interventions>
    <interventions>Other interventions - Ross River Virus (RRV) Vaccine

No Intervention: Safety assessment - Vaccine safety will be assessed in the period between 6 and 12 months after the 3rd vaccination in precursor Study 880801 based on diaries distributed to all subjects for documentation of SAEs or AESI. Females who became pregnant after the 3rd vaccination in Study 880801 will be followed until end of pregnancy.


Other interventions: Ross River Virus (RRV) Vaccine
Not applicable, no vaccine will be administered in this study. The RRV vaccine was administered in the precursor study.

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Incidence of SAEs and AESI, such as arthritis, Guillain Barré Syndrome (GBS), encephalitis, convulsions, Bell´s palsy, neuritis, vasculitis, demyelinating disorders (ADEM and myelitis) and vaccination failure - SAE = Serious adverse event, AESI = Adverse event of special interest</outcome>
      <timepoint>12 months after the third vaccination administered in precursor study 880801</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Subjects who participated in precursor Study 880801 and meet all of the following criteria:

          -  Subject received 3 RRV vaccinations in Study 880801

          -  Subject has completed Visit 6 in Study 880801

          -  Subject and, if applicable, subject´s parent(s)/legal guardian(s), understand the
             nature of the study and its procedures, agree to its provisions and provide written
             informed consent prior to study entry

          -  Subject provides written assent according to his/her age, if applicable</inclusivecriteria>
    <inclusiveminage>16</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Subject has participated in another clinical study other than Study 880801 involving
             an investigational product (IP) or investigational device within 30 days prior to
             enrollment or is scheduled to participate in another clinical study involving an IP or
             investigational device during the course of this study</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>1146</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/04/2013</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,VIC,WA</recruitmentstate>
    <hospital>Holdsworth House Medical Practice - Darlinghurst</hospital>
    <hospital>St. Vincent´s Hospital - Darlinghurst</hospital>
    <hospital>National Centre for Immunisation Research &amp; Surveillance, The Children´s Hospital Westmead - Westmead</hospital>
    <hospital>Wesley Research Institute Clinical Trials Centre, The Wesley Hospital - Auchenflower</hospital>
    <hospital>Cairns Base Hospital - Cairns</hospital>
    <hospital>QPID Clinical Trials Centre, Royal Children´s Hospital - Herston</hospital>
    <hospital>Dept of Microbiology &amp; Infectious Diseases - Bedford Park</hospital>
    <hospital>CMAX, a Division of the Institute of Drug Technology (IDT) Australia, Ltd. - North Adelaide</hospital>
    <hospital>Barwon Health - The Geelong Hospital, Dept Clinical &amp; Biomedical Sciencesl - Geelong</hospital>
    <hospital>Centre for Clinical Studies - Heidelberg</hospital>
    <hospital>Emeritus Research - Malvern East</hospital>
    <hospital>Linear Clinical Research - Nedlands</hospital>
    <hospital>Princess Margaret Hospital for Children - Perth</hospital>
    <postcode>2010 - Darlinghurst</postcode>
    <postcode>2145 - Westmead</postcode>
    <postcode>4066 - Auchenflower</postcode>
    <postcode>4870 - Cairns</postcode>
    <postcode>4029 - Herston</postcode>
    <postcode>5042 - Bedford Park</postcode>
    <postcode>5006 - North Adelaide</postcode>
    <postcode>3220 - Geelong</postcode>
    <postcode>3084 - Heidelberg</postcode>
    <postcode>3145 - Malvern East</postcode>
    <postcode>6009 - Nedlands</postcode>
    <postcode>6840 - Perth</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Nanotherapeutics, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to verify the long-term safety of a 2.5 µg, adjuvanted
      (aluminium hydroxide) dose of Ross River Virus (RRV) vaccine.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01604746</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Gerald Aichinger, MD</name>
      <address>Baxter Innovations GmbH</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>